# From Gila Monster to GLP-1 Revolution

Page: https://stenobird.com/podcast/fork-u-with-dr-terry-simpson-940256/from-gila-monster-to-glp-1-revolution
Text version: https://stenobird.com/podcast/fork-u-with-dr-terry-simpson-940256/from-gila-monster-to-glp-1-revolution.md
Podcast: [Fork U with Dr. Terry Simpson](https://stenobird.com/podcast/fork-u-with-dr-terry-simpson-940256)
Published: 2026-02-26T07:00:00+00:00
Episode link: https://forku.com/episode/from-gila-monster-to-glp-1-revolution
Audio file: https://op3.dev/e/episodes.captivate.fm/episode/121a5e94-cf95-4001-9047-9b6bd1ca48ed.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/fork-u-with-dr-terry-simpson-940256/episodes/from-gila-monster-to-glp-1-revolution
Duration seconds: 791

## Resource

Meanwhile, in a Laboratory In 1990, researchers isolated a peptide from Gila monster venom. Two years later, work from the Bronx VA Medical Center described exendin-4, a molecule that resembled human GLP-1 but lasted far longer in circulation. Human GLP-1 survives only minutes before the body breaks it down. Exendin-4 resisted that breakdown. That difference changed everything. Soon afterward, the first GLP-1 receptor agonist reached patients under the brand name Byetta . At the time, physicians used it to treat diabetes. No one called it a weight-loss drug. No one predicted it would reshape obesity medicine. And yet, the foundation was already in place. While I Was Operating At the Phoenix Indian Medical Center, I performed weight loss surgery in a population with some of the highest rates of type 2 diabetes in the world. Researchers there studied metabolism intensely. The “thrifty gene” hypothesis gained traction in that environment. Scientists asked whether efficient energy storage, once protective in scarcity, became harmful in abundance. At the same time, I watched something remarkable in the operating room. After gastric bypass, patients’ blood sugars often improved within days, before meaningful weight loss occurred. Hormones were shifting. Physiology was driving outcomes. Meanwhile, GLP-1 drugs evolved. Researchers lengthened their half-lives. Chemists modified their structures so they bound albumin and stayed active for days rather than minutes. Clinical trials expanded. Safety data accumulated. Eventually, semaglutide showed average weight loss approaching fifteen percent of body weight in obesity trials. Then tirzepatide, now marketed as Zepbound for obesity, exceeded 20 percent weight reduction in higher-dose studies. In addition, cardiovascular outcome tri…

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/fork-u-with-dr-terry-simpson-940256/episodes/from-gila-monster-to-glp-1-revolution/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/fork-u-with-dr-terry-simpson-940256/from-gila-monster-to-glp-1-revolution.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.